H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Cytokinetics (CYTK) to $136 from $120 and keeps a Buy rating on the shares following FDA approval of Myqorzo. The firm views the approval as a “big win” for Cytokinetics.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK: